Advertisement

Topics

Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

2014-07-23 21:11:43 | BioPortfolio

Summary

The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).

Description

Purpose:

to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin PDT for the treatment of prolonged unresolved Central Serous Chorioretinopathy (CSCR).

Study Design and Patient Recruitment:

This study was a prospective, randomized, consecutive, open-labeled, comparative interventional case series. Patients with symptomatic acute or chronic CSC of 3 weeks or more duration were recruited. Patients were offered treatment if they had worsening of symptoms or no subjective improvement since the onset of the CSC. Inclusion criteria included 1) patients with best-corrected visual acuity (BCVA) of 20/400 or better; 2) presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment (PED) involving the fovea on optical coherence tomography (OCT); 3) presence of active angiographic leakage in fluorescein angiography (FA) caused by CSC but not CNV or other diseases; and 4) abnormal dilated choroidal vasculature and other features in ICGA consistent with the diagnosis of CSC. Patients who received previous PDT or focal thermal laser photocoagulation for the treatment of CSC or had evidence of CNV, polypoidal choroidal vasculopathy, or other maculopathy on clinical examination, FA, or ICGA were excluded. Informed consent was obtained from all subjects. 12 patients in each group were planned to recruit in each group.

Modified Photodynamic Therapy with Half Dosage:

The Half Dosage PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) i.e., 3 mg/m2 infusion of verteporfin with a rationale that using lower dosage has less collateral damaging effects to the retina and choroid. Verteporfin was infused over 10 minutes followed by delivery of laser at 692 nm at 15 minutes from the commencement of infusion to target the area of choroidal dilation and hyperpermeability. Earlier laser application allowed less drug accumulation at the RPE layer and less drug less toxicity at the RPE. A total light energy of 50 J/cm2 over 83 seconds was delivered to the area of choroidal hyperperfusion as observed in ICGA instead of the angiographic leakage sites shown in FA. Only the area of choroidal vascular abnormality that was supposed to cause the serous detachment involving the macula was considered to be treated. To avoid overtreatment on the choroidal vasculature in causing choroidal ischemia, the laser spot size was set at a maximum of 4,500 µm. This restriction in laser spot size is adequate, from our previous report, to reverse the serous macular detachment by reducing the choroidal extravascular leakage and sub-RPE hydrostatic pressure at the macular area. In patients with bilateral CSC, only one eye was recruited for the study, and the eye with thicker central retinal thickness on OCT was chosen. After treatment, patients were given protective spectacles and instructed to avoid strong light for 3 days.

Modified Photodynamic Therapy with Half fluence:

The Half fluence PDT protocol for CSC was performed using half the normal duration of verteporfin laser time (Visudyne, Novartis AG, Bülach, Switzerland) All patients received a bolus infusion of 6 mg/m2 body surface area over 1 minute. Patients were assigned to treatment protocols, using a fluence of 25 J/cm2. In the 25-J/cm2 group, patients received an irradiance of 600 mW. Depending on the irradiance, the time of photosensitization was 42 seconds. A total light energy of 25 J/cm2 over 42 seconds was delivered to the area of choroidal hyperperfusion as observed in ICGA instead of the angiographic leakage sites shown in FA. Only the area of choroidal vascular abnormality that was supposed to cause the serous detachment involving the macula was considered to be treated. To avoid overtreatment on the choroidal vasculature in causing choroidal ischemia, the laser spot size was set at a maximum of 4,500 µm. This restriction in laser spot size is adequate, from our previous report, to reverse the serous macular detachment by reducing the choroidal extravascular leakage and sub-RPE hydrostatic pressure at the macular area. In patients with bilateral CSC, only one eye was recruited for the study, and the eye with thicker central retinal thickness on OCT was chosen. After treatment, patients were given protective spectacles and instructed to avoid strong light for 3 days.

Documentation:

Patients were seen for regular follow-up visits within 1 week before and at day 1, week 1, week 4, and month 3 after treatment. A standardized evaluation was performed at each visit including best corrected visual acuity according to the guidelines of the Early Treatment Diabetic Retinopathy Study (ETDRS), confocal scanning laser fluorescein angiography (FA), ICGA (Heidelberg Engineering, Dossenheim, Germany), fundus photography, and a complete eye examination. Selected patients were imaged with optical coherence tomography (OCT).

The main outcome measures were choroidal perfusion changes, as documented by early and late ICGA. A PDT-induced increase in collateral leakage area seen by late FA 1 day after PDT was defined as a secondary outcome, as was primary CNV closure documented by early FA. Best-corrected visual acuity was documented for safety evaluation. Data were statistically analyzed with the Wilcoxon signed-rank and Wilcoxon rank sum tests. Statistical significance was defined as P <0.05.

Procedures for Evaluation:

The Image J, (software ; NIH, USA), an imaging software developed for analysis and visualization of images obtained with grayscale photograph, was used forplanimetric evaluation of the area of hypofluorescence detected by ICGA and the area of PDT-induced leakage seen on FA. Choriocapillary hypoperfusion and nonperfusion were graded according to a scale. Angiographies were evaluated by two masked readers, and planimetricand grading results of both readers were averaged.

Follow-Up Examinations:

Patients were assessed at baseline and followed at day 1, 7, 30, 90 and 180 after PDT. At the baseline and post-PDT visits, BCVA was measured by certified optometrists with the Early Treatment Diabetic Retinopathy Study (ETDRS) logarithm of the minimum angle of resolution (logMAR) chart at 4 m or Snellen chart at 6 m being converted to logMAR equivalent for analysis. OCT recordings were performed using an OCT 3 machine (StratusOCT, Carl Zeiss Meditec Inc., Dublin, CA). Both vertical and horizontal scans of 6.0 mm centered on the fovea were obtained for measurement of central foveal thickness. OCT central foveal thickness was measured manually using the retinal thickness mode and is defined as the distance between the inner surface of the RPE and the inner surface of the neurosensory retina at the fovea. FA and ICGA were performed in all patients at baseline, month 1, and 3 after PDT. Additional FA and ICGA were carried out in patients with persistence or recurrence of CSC during the follow-up period. CSC was classified according to FA findings into two groups: 1) chronic CSC with serous retinal detachment and focal leakage (Group 1); or 2) chronic CSC with diffuse leakage that had an RPE transmission defect in early phase and diffuse angiographic leakage in mid to late phases (Group 2). Features of CSC in ICGA were delineated according to the original descriptions.

Data Analysis:

The main outcome measures of the study included the serial changes in logMAR BCVA and OCT central foveal thickness. Other outcome measures included complications and FA and ICGA changes during the follow-up period. Serial comparisons of mean logMAR BCVA and OCT central foveal thickness were performed using the nonparametric Wilcoxon-signed rank test and two-tailed t-test, respectively. Categorical variables were analyzed using the chi-square test and Fisher exact test. Statistical analysis was performed using SPSS and a P value of <=0.05 was considered statistically significant.

Study Design

Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Central Serous Chorioretinopathy

Intervention

Verteporfin PDT, half-dose, verteporfin PDT, half-fluence

Location

Shin Kong Wu Ho-Su Memorial Hospital
Taipei
Taiwan
111

Status

Recruiting

Source

Shin Kong Wu Ho-Su Memorial Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:11:43-0400

Clinical Trials [1850 Associated Clinical Trials listed on BioPortfolio]

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of...

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced fluence PDT combination therapy with ranibizumab. The researchers hope to gain information regardi...

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The et...

Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.

To determine if Visudyne photodynamic therapy (low or very low fluence rate) combined with intravitreal injections of bevacizumab (Avastin) compared with bevacizumab alone will, with simil...

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

This study aims to compare the efficacy of ranibizumab with verteporfin PDT used in combination with ranibizumab or with verteporfin PDT alone in achieving complete regression of polyps me...

PubMed Articles [10436 Associated PubMed Articles listed on BioPortfolio]

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.

To compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT...

Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

To evaluate the efficacy and safety of full-fluence photodynamic therapy (PDT) and half-fluence PDT in chronic central serous chorioretinopathy (CSC).

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy.

This study evaluated changes in choroidal vascularity after half-fluence photodynamic therapy (HF-PDT) in patients with central serous chorioretinopathy (CSC) using swept-source optical coherence tomo...

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy.

To identify the angiographic and tomographic prognostic factors of chronic central serous chorioretinopathy (CSC) treated with half-dose photodynamic therapy (PDT).

Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Different modes of photodynamic therapy (PDT) were described for treatment of central serous chorioretinopathy (CSC). The purpose of the current study was to evaluate the outcome of half-time PDT in c...

Medical and Biotech [MESH] Definitions

The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.

Inorganic compounds that contain TECHNETIUM as an integral part of the molecule. Technetium 99m (m=metastable) is an isotope of technetium that has a half-life of about 6 hours. Technetium 99, which has a half-life of 210,000 years, is a decay product of technetium 99m.

Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)

A nucleus located in the caudal half of the amygdala. It is a primary region involved in controlling responses and receives many intrinsic GABAergic amygdaloid connections.

The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, atomic number 43, and atomic weight 98.91. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.

More From BioPortfolio on "Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial